Shopping Cart
Remove All
Your shopping cart is currently empty
Gatralimab (GZ-402668) is a next-generation humanized anti-CD52 monoclonal antibody for which phase 1 clinical trial data indicate it successfully achieves the intended pharmacodynamic effect of lymphocyte depletion followed by subsequent repopulation, all with an acceptable safety profile, supporting its further investigation about relapsing-remitting multiple sclerosis (MS).
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $247 | - | In Stock | |
| 5 mg | $647 | - | In Stock | |
| 10 mg | $987 | - | In Stock |
| Description | Gatralimab (GZ-402668) is a next-generation humanized anti-CD52 monoclonal antibody for which phase 1 clinical trial data indicate it successfully achieves the intended pharmacodynamic effect of lymphocyte depletion followed by subsequent repopulation, all with an acceptable safety profile, supporting its further investigation about relapsing-remitting multiple sclerosis (MS). |
| Synonyms | GZ-402668 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | < 1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID |
| Cas No. | 1826020-80-7 |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.